3-MeO-PCMo

At 100–200 mg oral, dissociative effects become clearly perceptible. Bodily lightness develops into a warm, pleasant tingling — early tactile euphoria. Cognitive disconnection begins: thoughts feel slightly distant, and spatial disorientation emerges as a subtle unfamiliarity with surroundings. Visual processing suppression softens the visual field. Touch suppression reduces tactile sensitivity. Motor control remains largely intact but may feel slightly imprecise. Mild nausea is possible during the onset phase. Onset remains 1–2 hours. Functional impairment is mild but present — reading and conversation require slightly more effort. Total commitment is approximately 5–6 hours including aftereffects.

At 50 mg oral, effects are minimal and easily missed. A faint sense of bodily lightness may emerge after a 1–2 hour delay, accompanied by subtle mood elevation. Cognitive effects are barely distinguishable from baseline — slight softening of internal monologue at most. Physical sensations are limited to mild warmth or tingling that may go unnoticed. No meaningful motor control impairment or sensory suppression. Appetite and sleep are generally unaffected. The slow onset is the primary practical concern at this tier. Wait a full 2 hours before considering whether effects have materialized — premature redosing is a significant risk with this substance at every tier.

At 200–300 mg oral, a full dissociative state develops. Depersonalization and derealization are clearly present — the body feels distant, the environment surreal. Cognitive disconnection is prominent: thought deceleration, analysis suppression, and impaired memory formation define the cognitive landscape. Music enhancement is often reported. A warm, motionless body sensation with tactile euphoria is characteristic of this tier. Motor control impairment is moderate — walking is possible but unsteady. Touch suppression is noticeable. Spontaneous body sensations and bodily lightness contribute to the floating quality. Time alteration distorts subjective duration. Euphoria and anxiety suppression are common. Immersion enhancement deepens engagement with music or visual media. Functional impairment is significant — plan for 6+ hours of commitment.

At 300–400 mg oral, deep dissociation dominates the experience. Depersonalization becomes near-total — the body may feel entirely absent. Memory suppression is significant, with substantial amnesia for portions of the experience. Cognitive disconnection is severe, and reality testing is substantially impaired. Motor control impairment is marked — standing and walking become difficult or inadvisable. Perspective distortion and visual processing suppression intensify. Time alteration may produce the sense that hours have passed in minutes, or vice versa. Spontaneous body sensations may feel dreamlike. Mania and delusions of sobriety are reported at this tier, creating a paradoxical sense of normalcy despite severe impairment. Compulsive redosing urge may be present. Disinhibition increases risk of impulsive behavior. This tier carries elevated psychological risk.

At 400+ mg oral, extreme dissociation approaches complete cognitive disconnection. Amnesia may be near-total for the duration. Delirium, confusion, and disorientation are likely. The boundary between waking experience and unconsciousness may blur. Complete motor incapacitation is expected — the user will likely be unable to stand or walk safely. Nausea and vomiting risk increases. Respiratory and cardiovascular effects become a genuine safety concern, particularly in combination with any CNS depressant. Psychological distress is a significant risk: psychotic features, severe mania, paranoia, and dangerous behavior driven by delusions of sobriety are all possible. This tier approaches the unknown toxicity threshold — no LD50 or maximum tolerated dose has been established. Emergency support should be immediately accessible.